AUTHOR=Chen Juan , Liu Li , Ma Runzhi , Pang Aiming , Yang Donglin , Chen Xin , Wei Jialin , He Yi , Zhang Rongli , Zhai Weihua , Ma Qiaoling , Jiang Erlie , Han Mingzhe , Feng Sizhou 

TITLE=Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1025885

DOI=10.3389/fonc.2022.1025885

ISSN=2234-943X

ABSTRACT=<sec><title>Objective</title><p>This study aims to compare the characteristics of early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) and non-ETP ALL patients and the outcomes of these patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT).</p></sec><sec><title>Method</title><p>A total of 57 patients with T-cell acute lymphoblastic leukemia/lymphoma receiving allo-HSCT at our center between January 2016 and March 2022 were enrolled in the study. Twenty-eight patients were diagnosed as ETP-ALL/LBL (28/57, 49.12%) in the cohort.</p></sec><sec><title>Results</title><p>The baseline characteristic was not significantly different between the two groups. The median time for myeloid engraftment was 14 days (ranged from 11 to 21) <italic>versus</italic> 14 days (ranged from 10 to 20) (<italic>P</italic> = 0.067) and 18 days (ranged from 12 to 27) <italic>versus</italic> 15.5 days (ranged from 12 to 72) (<italic>P</italic> = 0.183) for platelet engraftment in the ETP-ALL/LBL and non-ETP ALL groups, respectively. There was no significant difference in 5-year overall survival (54.74% ± 10.33% <italic>vs</italic>. 64.20% ± 10.30%, <italic>P</italic> = 0.786), relapse-free survival (56.22% ± 10.11% <italic>vs</italic>. 57.17% ± 12.71%, <italic>P</italic> = 0.841), cumulative incidence of relapse (30.14% ± 9.85% <italic>vs</italic>. 22.79% ± 8.24%, <italic>P</italic> = 0.774), and non-relapse mortality (19.52% ± 8.99% <italic>vs</italic>. 25.95% ± 14.44%, <italic>P</italic> = 0.967) between the two groups. The incidence of acute graft <italic>versus</italic> host disease (aGVHD) (<italic>P</italic> = 0.922), II–IV aGVHD (<italic>P</italic> = 0.940), III–IV aGVHD (<italic>P</italic> = 0.664), cytomegalovirus infection (<italic>P</italic> = 0.862), Epstein–Barr virus infection (<italic>P</italic> = 0.610), and severe bacterial infection (<italic>P</italic> = 0.145) was also similar.</p></sec><sec><title>Conclusion</title><p>The prognosis of patients with ETP-ALL/LBL was similar to non-ETP ALL patients when they received allo-HSCT.</p></sec>